A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation

被引：0
|
作者：
Lee, Elizabeth K.
Hendrickson, Andrea E. Wahner
Colon-Otero, Gerardo
Pickett, Cheryl A.
Xiong, Niya
Cheng, Su-Chun
Polak, Madeline
Sawyer, Hannah
Hayes, Martin
Matulonis, Ursula A.
Shapiro, Geoffrey I.
Konstantinopoulos, Panagiotis A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B041
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer
    Iwasa, Satoru
    Shitara, Kohei
    Takahashi, Shunji
    Park, Haeseong
    Kadowaki, Shigenori
    Modi, Shanu
    Nonagase, Yoshikane
    Tamura, Kenji
    Yamaguchi, Kensei
    Muro, Kei
    Tsurutani, Junji
    Shahidi, Javad
    Lee, Caleb C.
    Sugihara, Masahiro
    Kawaguchi, Yoshinori
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Yoshino, T.
    Iwata, H.
    Tamura, K.
    Takahashi, S.
    Redfern, C.
    Modi, S.
    Doi, T.
    Kawakami, H.
    Taniguchi, H.
    Takashima, A.
    Yamaguchi, K.
    Fisher, J.
    Li, B.
    Saito, K.
    Fujisaki, Y.
    Sugihara, M.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer
    Tsurutani, J.
    Park, H.
    Doi, T.
    Modi, S.
    Takahashi, S.
    Nakagawa, K.
    Krop, I.
    Waqar, S.
    Yoh, K.
    Li, B.
    Taira, S.
    Jikoh, T.
    Singh, J.
    Sugihara, M.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S324 - S324
  • [4] Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies
    Tsurutani, J.
    Doi, T.
    Iwata, H.
    Takahashi, S.
    Modi, S.
    Tamura, K.
    Shitara, K.
    Taniguchi, H.
    Taira, S.
    Li, B.
    Shimomura, A.
    Sato, Y.
    Akiyama, K.
    Fujisaki, Y.
    Lee, C.
    Yver, A.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers
    Modi, Shamu
    Tsurutani, Junji
    Takahashi, Shunji
    Iwata, Hiroji
    Park, Haeseong
    Redfern, Charles H.
    Doi, Toshihiko
    Li, Bob
    Iwasa, Tsutomu
    Taira, Shunichiro
    Hattori, Masaya
    Ma, Cynthia X.
    Fisher, Jennifer M.
    Naito, Yoichi
    Yonemori, Kan
    Kawasaki, Yui
    Saito, Kaku
    Jikoh, Takahiro
    Shahidi, Javad
    Lee, Caleb C.
    Yver, Antoine
    Tamura, Kenji
    CANCER RESEARCH, 2018, 78 (04)
  • [6] A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [7] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
    Iwata, Hiroji
    Tamura, Kenji
    Doi, Toshihiko
    Tsurutani, Junji
    Modi, Shanu
    Park, Haeseong
    Krop, Ian E.
    Sagara, Yasuaki
    Redfern, Charles H.
    Murthy, Rashmi Krishna
    Redman, Rebecca A.
    Shitara, Kohei
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
  • [9] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
    Modi, S.
    Tsurutani, J.
    Tamura, K.
    Park, H.
    Sagara, Y.
    Murthy, R.
    Iwata, H.
    Krop, I. E.
    Doi, T.
    Redfern, C.
    Moreno-Aspitia, A.
    Redman, R.
    Lee, C.
    Sugihara, M.
    Fujisaki, Y.
    Takahashi, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345